Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs

  • Published on 06/10/2024
  •  Reading time: 8 min.

Svenja Müller 1,2, Laura Maintz 1,2, Thomas Bieber 2,3

1 Department of Dermatology and Allergy University Hospital Bonn Bonn Germany
2 Christine Kühne Center for Allergy Research and Education Davos (CK‐CARE) Davos Switzerland
3 Davos BioSciences Davos Switzerland


Atopic dermatitis (AD) represents the most common skin disease characterized by heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic therapies for AD have been approved: the biologics dupilumab (anti‐interleukin‐4 receptor (IL‐4R) α in 2017), tralokinumab (anti‐IL‐13 in 2021), lebrikizumab (anti‐IL‐13 in 2023), and the oral janus kinase (JAK) inhibitors (JAKi) targeting JAK1/2 (baricitinib in 2020...


To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Dermatology

Receive our newsletter to stay up to date with the latest news in Dermatology